Recent research on Medicare Advantage has tracked competition in local markets and investigated the rates of biosimilar drug uptake in both MA and traditional Medicare.
Here are five Medicare Advantage findings Becker's has reported since Nov. 16.
- Medicare Advantage beneficiaries are more likely to be prescribed biosimilar drugs than their counterparts in traditional Medicare, a study published in JAMA Health Forum found.
- Seven in 10 metropolitan areas have "highly concentrated " Medicare Advantage markets, according to the AMA's annual "Competition in Health Insurance" report. In 90% of metropolitan areas, one payer has at least a 30% MA market share. In 31% of markets, one insurer had a share of 50% or more.
- The Hospital Insurance Trust Fund would be solvent until 2048 if traditional Medicare utilization levels were similar to those under Medicare Advantage, according to research published by AHIP and conducted by Avalere. The Medicare Board of Trustees report has previously projected that the fund will be insolvent by 2031.
- Fewer Medicare Advantage beneficiaries are choosing no-premium plans for 2024, according to eHealth's November snapshot report that tracks MA and Part D plans selected by beneficiaries in the first half of the current annual enrollment period.
- Differences in the clinicians Medicare Advantage and traditional Medicare beneficiaries see have some effect on differences in avoidable hospitalization rates between the two programs, a study published in JAMA Health Forum found.